Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Horizon scan of novel and upcoming AML therapies

Amir Fathi • 24 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Antibodies KO-539 Venetoclax

Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, summarizes the latest updates in the field of acute myeloid leukemia (AML), highlighting a new menin inhibitor and studies of novel combinations of IDH inhibitors and FLT3 inhibitors, such as with the BCL2 inhibitor venetoclax, as well as the future role of antibody-drug conjugates, bispecific antibodies and CAR T-cell therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Amir Fathi

1:17
Venetoclax plus azacitidine vs intensive chemotherapy induction in fit patients with AML
Amir Fathi • 21 Nov 2023
2:04
Hot topics in the AML space: menin inhibitors
Amir Fathi • 21 Nov 2023
1:44
Improving maintenance therapy in AML: exploring the role of IDH inhibitors
Amir Fathi • 21 Nov 2023
1:12
Managing adverse risk AML: clinical considerations & future outlooks
Amir Fathi • 21 Nov 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals